Wedbush Decreases Earnings Estimates for Astria Therapeutics
Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) – Equities researchers at Wedbush reduced their Q2 2025 EPS estimates for Astria Therapeutics in a research note issued on Wednesday, May 14th. Wedbush analyst L. Chico now anticipates that the biotechnology company will earn ($0.59) per share for the quarter, down from their previous forecast of ($0.47). […]
Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) – Equities researchers at Wedbush reduced their Q2 2025 EPS estimates for Astria Therapeutics in a research note issued on Wednesday, May 14th. Wedbush analyst L. Chico now anticipates that the biotechnology company will earn ($0.59) per share for the quarter, down from their previous forecast of ($0.47). […]
